Inivata is attending The Molecular Medicine Tri Conference Feb 19-24, San Francisco
Davina Gale, an Inivata co-founder and Business Development Manager is attending The Molecular Medicine Tri Conference Feb 19-24 in San Francisco. Davina will also be joining a workshop with Horizon Discovery entitled ‘Enabling Sequencing Technologies to Reach Their Full Potential – bringing ctDNA to the clinic’ taking place in room #130 on Tuesday 21st February, 3:40-4:10pm. If you would like to meet with Davina during the conference please contact us.
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high caliber publications. Its lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.